ZLAB - Why did NovoCure stock surge today? Phase 3 data for lung cancer candidate
- NovoCure Limited ( NASDAQ: NVCR ) closed up ~68% on Thursday thanks to positive late-stage data on the Tumor Treating Fields (TTFields) therapy for non-small cell lung cancer.
- The company is partnered with Zai Lab ( NASDAQ: ZLAB ) on TTFields. The Chinese biotech closed up ~42% .
- Read Seeking Alpha contributor From Growth to Value's argument that NovoCure ( NVCR ) is set to soar in 2023.
For further details see:
Why did NovoCure stock surge today? Phase 3 data for lung cancer candidate